Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer

NCT07641036 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma
Extrahepatic Cholangiocarcinoma
Gallbladder Carcinoma
Biliary Tract Cancer

Interventions

BIOLOGICAL: EB-HC01 dual-target CARNK cells
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Beijing Biotech